{
    "clinical_study": {
        "@rank": "99105", 
        "arm_group": [
            {
                "arm_group_label": "aMIL Arm", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)"
            }, 
            {
                "arm_group_label": "No aMIL", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)"
            }
        ], 
        "brief_summary": {
            "textblock": "This research is being done to find out if altering the immune system by giving Prevnar\n      vaccine, Tadalafil, and activated marrow infiltrating lymphocytes (MILs) can improve\n      outcomes for multiple myeloma patients who receive a standard autologous stem cell\n      transplant."
        }, 
        "brief_title": "Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma", 
        "completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 - 80 years old;\n\n          -  Patients with active myeloma requiring systemic treatment;\n\n          -  Newly diagnosed patients.  Relapsed myeloma patients that have not previously had a\n             transplant;\n\n          -  Meeting criteria for high-risk disease;\n\n          -  Measurable serum and/or urine M-protein from prior to induction therapy documented\n             and available.  A positive serum free lite assay is acceptable;\n\n          -  ECOG performance status of 0 - 2 (see Appendix C).\n\n          -  Meet all institutional requirements for autologous stem cell transplantation;\n\n          -  The patient must be able to comprehend and have signed the informed consent;\n\n          -  Patients must have had > than PR after last therapy.\n\n        Exclusion Criteria:\n\n          -  Diagnosis of any of the following cancers:\n\n               -  POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,\n                  endocrinopathy, monoclonal protein [M-protein] and skin changes);\n\n               -  Non-secretory myeloma (no measurable protein on Serum Free Lite Assay);\n\n          -  Diagnosis of amyloidosis;\n\n          -  Previous hematopoietic stem cell transplantation;\n\n          -  Use of corticosteroids (glucocorticoids) within 21 days of bone marrow collection;\n\n          -  Use of any myeloma-specific therapy within 21 days of bone marrow collection;\n\n          -  Infection requiring treatment with antibiotics, antifungal, or antiviral agents\n             within seven  days of registration;\n\n          -  Participation in any clinical trial within 21 days of bone marrow collection\n             involving an investigational drug or device;\n\n          -  History of malignancy other than multiple myeloma within five years of registration,\n             except adequately treated basal or squamous cell skin cancer;\n\n          -  History of an autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis,\n             systemic lupus erythematosis) requiring active systemic treatment. Hypothyroidism\n             without evidence of Grave's disease or Hashimoto's thyroiditis is permitted.\n\n          -  HTLV 1 or 2 positive;\n\n          -  Known hypersensitivity to Prevnar or any of its components;\n\n          -  Contraindication to phosphodiesterase-5 inhibitors (e.g. currently on nitrates)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858558", 
            "org_study_id": "J1343", 
            "secondary_id": "NA_00084466"
        }, 
        "intervention": [
            {
                "arm_group_label": "aMIL Arm", 
                "description": "Patients will receive Prevnar vaccine followed by aMIL harvest. On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.", 
                "intervention_name": "aMIL", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "aMIL Arm", 
                    "No aMIL"
                ], 
                "description": "Patients will receive Prevnar vaccine followed by aMIL harvest. On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.", 
                "intervention_name": "No aMIL", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tadalafil", 
                "Lenalidomide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "contact": {
                "last_name": "Ivan Borrello, M.D.", 
                "phone": "410-955-4967"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21231"
                }, 
                "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
            }, 
            "investigator": {
                "last_name": "Ivan Borrello, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma", 
        "overall_contact": {
            "email": "iborrell@jhmi.edu", 
            "last_name": "Ivan Borrello, M.D.", 
            "phone": "410-955-4967"
        }, 
        "overall_contact_backup": {
            "email": "akramer3@jhmi.edu", 
            "last_name": "Amy Sidorski, Nurse Practitioner"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Ivan Borrello, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the efficacy of Activated Marrow Infiltrating Lymphocytes (MILs) in prolonging progression free survival (PFS) in patients with high risk multiple myeloma followed by Autologous Stem Cell Transplantation (ASCT).", 
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858558"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events related to the infusion of  activated MILs will be collected.", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "The Leukemia and Lymphoma Society", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}